Progression-free and overall survival in patients with recurrent GBM treated with Bevacizumab versus Bevacizumab/Lomustine
Autor: | Heiland, DH, Masalha, W, Franco, P, Machein, M, Weyerbrock, A |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: | |
Zdroj: | 66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20150607-20150610; Karlsruhe; DOCMI.09.04 /20150602/ |
DOI: | 10.3205/15dgnc301 |
Popis: | Objective: Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma (GBM). Recent studies could not show a positive effect of BEV in first-line therapy of GBM. BEV improved the progression-free-survival (PFS) without prolonging overall survival (OS). Lomustine (CCNU) monotherapy[for full text, please go to the a.m. URL] 66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) |
Databáze: | OpenAIRE |
Externí odkaz: |